Paula Videira, leader of the Glycoimmunoly Lab at UCIBIO in FCT NOVA, founded the spinoff CellmAbs SA, together with the FCT NOVA alumnus Nuno Prego Ramos, researcher in the same lab. Formally launched in June 2019, has already raised an important first round of investment by Portugal Ventures, a venture capital company. This investment will allow developing a new class of immunotherapies for cancer treatments.
The project, focused on the area of glycobiology and oncobiology, is centered on the identification of distinct and specific elements of tumor cells. The CellmAbs SA technology results from research developed at the Glycoimmunology Lab in the last few years, with the collaboration of other UCIBIO researchers, including Carlos Novo and Angelina Palma. The technology allows the development of immunotherapies against solid tumors, as well as the development of innovative treatments and personalized medicines, namely the Chimeric antigen-receptor-engineered T cells (CAR-T cells) therapy.
This project is already attracting the attention of various multinational pharmaceutical companies. “The spinoff CellmAbs from NOVA University of Lisbon is an output of the great science work that is being done in academia, showing a successful example of technology transfer from academia research to the market. Our technology represents one of the greatest recent breakthroughs in the field of oncology worldwide. In the absence of effective treatments for most of the solid tumors that kill millions of people every year, it is emergent to provide innovative treatments. Therefore, the investment by Portugal Ventures is essential, as it will allow us to perform the trials we need to go forward to the pre-clinical stage.”, explain the UCIBIO researchers co-founders of CellmAbs SA, Nuno Prego Ramos and Paula Videira, also professor at the Department of Life Sciences at FCT NOVA.
In the news